Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice concerning the bulk exercise, completion of exercise and monthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)

Of the 19th Stock Acquisition Rights allotted to EVO FUND, 43,800 units were exercised and 4,380,000 shares were delivered between 2 and 18 November 2026. As a result, no units remained unexercised and the exercise was completed.

Worth reading
66In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
4380000
shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)

発行・処分する株式数4,380,000Shares

4,380,000 shares (new shares)

Intended allottee
EVO FUND (allottee of the Stock Acquisition Rights already issued)
Existing Shares and Increase
+4.50%Rate of increase
115,954,098 shares120,334,098Shares

4.5% (exercise ratio relating to the exercise restriction)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥28.0 on 10 November, ¥28.0 on 13 November and ¥28.0 on 18 November. The stated exercise price on other dates was ¥28.0, ¥29.0 or ¥30.0. Details of the adjustment clause are Not disclosed in this document.
Number of Stock Acquisition Rights
Total issued: 240,000 units; exercised since the beginning of the month: 43,800 units; currently unexercised: 0 units
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
12 June 2026: Issuance of the 19th stock acquisition rights (with exercise price adjustment clause), with EVO FUND as the allottee. Amount: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
Number of shares to be issued or disposed of4,380,000 shares (new shares)
Intended allotteeEVO FUND (allottee of the Stock Acquisition Rights already issued)
Dilution Rate4.5% (exercise ratio relating to the exercise restriction)
Total number of issued shares115,954,098 shares (as of the end of the month preceding the target month) → 120,334,098 shares (calculated figure assuming all 4,380,000 new shares are delivered)
Exercise price¥28.0 on 10 November, ¥28.0 on 13 November and ¥28.0 on 18 November. The stated exercise price on other dates was ¥28.0, ¥29.0 or ¥30.0. Details of the adjustment clause are Not disclosed in this document.
Number of Stock Acquisition RightsTotal issued: 240,000 units; exercised since the beginning of the month: 43,800 units; currently unexercised: 0 units
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing12 June 2026: Issuance of the 19th stock acquisition rights (with exercise price adjustment clause), with EVO FUND as the allottee. Amount: Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because bulk exercises occurred between 2 and 18 November 2026, and all exercises were completed as of 18 November.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.